Core Viewpoint - Axogen, Inc. reported strong financial results for Q1 2025, highlighting robust revenue growth and progress towards long-term objectives, with a focus on enhancing sales productivity and commercial execution [3][5]. Financial Results - Q1 2025 revenue reached $48.6 million, marking a 17.4% increase compared to Q1 2024 [6]. - Gross margin for Q1 2025 was 71.9%, down from 78.8% in Q1 2024, attributed to increased product costs and inventory write-offs [6][7]. - The net loss for the quarter was $3.8 million, or $0.08 per share, an improvement from a net loss of $6.6 million, or $0.15 per share, in Q1 2024 [6][20]. - Adjusted net loss for the quarter was $0.9 million, or $0.02 per share, compared to $2.7 million, or $0.06 per share, in Q1 2024 [6][20]. - Adjusted EBITDA was $2.9 million for the quarter, up from $1.0 million in Q1 2024 [6][20]. Business Highlights - Revenue growth was broad-based across the product portfolio, with double-digit growth in all markets, including Extremities, Oral Maxillofacial & Head and Neck, and Breast [7]. - The FDA accepted the filing of the Biologics License Application (BLA) for Avance® Nerve Graft, with a goal date for approval set for September 5, 2025 [7]. - Regulatory milestones completed in Q1 2025 included a mid-cycle meeting with the FDA and clinical trial site inspections [7]. - Lindsey Hartley, CPA, was appointed as the new Chief Financial Officer effective May 12, 2025, succeeding Nir Naor [7]. 2025 Financial Guidance - The company maintains its full-year revenue growth guidance in the range of 15% to 17% and expects gross margin to be between 73% and 75% [5]. - The company anticipates being net cash flow positive for the full year [5].

Core Insights - Axogen, Inc. has appointed Lindsey Hartley, CPA, as the new Chief Financial Officer, effective May 12, 2025, succeeding Nir Naor, who will remain in an advisory role until July 1, 2025 [1][2] Company Overview - Axogen, Inc. is a leader in developing and marketing surgical solutions for peripheral nerve injuries, focusing on restoring health and improving quality of life through innovative technologies [3][4] - The company offers a range of products including Avance Nerve Graft, Axoguard Nerve Connector, and Axoguard Nerve Protector, which are designed to aid in the repair and protection of peripheral nerves [4][5] Leadership Transition - Michael Dale, President and CEO of Axogen, expressed gratitude for Nir Naor's contributions, highlighting improvements in operating expense and cash flow management during his tenure [2] - Lindsey Hartley brings over 19 years of financial leadership experience, having previously served as Vice President, Corporate Controller at Axogen, where she improved financial reporting processes and reduced month-end close time by 40% [2][3] Strategic Focus - Lindsey Hartley aims to emphasize financial discipline and strategic growth initiatives to support Axogen's mission of restoring nerve function and transforming patients' lives [3]

ALACHUA and TAMPA, Fla., April 24, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that it will report 2025 first quarter financial results on Thursday, May 8, 2025, before the market opens. Axogen management will host an investment-community conference call and webcast at 8 a.m. ET following the release. Investors interested in participating in the conference call by phone may do s ...

ALACHUA, Fla. and TAMPA, Fla., March 24, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced the appointment of Rick Ditto as Vice President, Global Health Economics, Reimbursement & Policy. Mr. Ditto will report to Michael Dale, President, and Chief Executive Officer, and will lead the development of the coverage and reimbursement-related strategies required to support Axogen’s mission ...

Financial Performance - Revenues for the year ended December 31, 2024 increased by $28,326, or 17.8%, to $187,338 compared to $159,012 for the year ended December 31, 2023, driven by a 9.0% increase in unit volume and a 5.5% impact from product mix changes [350]. - Gross profit for the year ended December 31, 2024 was $141,977, an increase of $20,108, or 16.5%, compared to $121,869 for the year ended December 31, 2023, with a gross margin of 75.8% [351]. - Net loss for 2024 decreased to $9.96 million compared to a net loss of $21.72 million in 2023, indicating improved financial performance [422]. - Total revenues for 2024 reached $187.34 million, a 17.8% increase from $159.01 million in 2023 [422]. - Gross profit for 2024 was $141.98 million, up from $121.87 million in 2023, reflecting a gross margin improvement [422]. Expenses and Costs - Total costs and expenses increased by $1,933, or 1.3%, to $145,264 for the year ended December 31, 2024, primarily due to $9,745 in compensation costs [352]. - Sales and marketing expenses increased by $881, or 1.1%, to $78,461 for the year ended December 31, 2024, attributed to $6,028 in compensation costs [353]. - Research and development expenses increased by $428, or 1.6%, to $27,767 for the year ended December 31, 2024, primarily due to product development and clinical expenses [354]. - General and administrative expenses increased by $624, or 1.6%, to $39,036 for the year ended December 31, 2024, mainly due to $921 in bad debt expense [355]. - Total other expense increased by $6,423, or 2528.7%, to $6,677 for the year ended December 31, 2024, primarily due to an increase in interest expense of $5,372 [356]. Cash Flow and Liquidity - Net cash provided by operating activities was $4,535 for the year ended December 31, 2024, compared to net cash used in operating activities of $5,716 for the year ended December 31, 2023 [369]. - Net cash used in investing activities was $10,297 for the year ended December 31, 2024, compared to net cash provided by investing activities of $19,253 for the year ended December 31, 2023 [371]. - Cash and cash equivalents at the end of 2024 were $27.55 million, down from $31.02 million in 2023 [420]. - As of December 31, 2024, the company had $50,000 outstanding in indebtedness under a credit facility, with $35,000 maturing on June 30, 2027, and $15,000 maturing on June 30, 2028 [376]. Inventory and Assets - The company’s total property and equipment, net, was $84,667,000 as of December 31, 2024, down from $88,730,000 in 2023 [492]. - The company's inventory as of December 31, 2024, was $33,183,000, an increase from $23,020,000 in 2023 [491]. - The provision for inventory write-down was $6,989,000 for the year ended December 31, 2024, compared to $1,939,000 in 2023 [491]. - Total current assets increased to $99.22 million in 2024 from $88.00 million in 2023, driven by higher inventory levels [420]. Shareholder Information - The company reported a weighted average of 44.26 million common shares outstanding in 2024, compared to 42.88 million in 2023 [422]. - The net loss attributable to common shareholders for the year ended December 31, 2024, was $9.964 million, compared to $21.716 million in 2023 and $28.948 million in 2022 [518]. - The weighted average common shares outstanding increased to 44,257,754 in 2024 from 42,878,543 in 2023 [518]. Research and Development - Research and development expenses for 2024 were $27.77 million, slightly up from $27.34 million in 2023, indicating continued investment in innovation [422]. - The company plans to continue focusing on the commercialization of its nerve regeneration technologies, including new product developments [430]. Debt and Interest - Long-term debt, net of debt discount and financing fees, increased to $47,496,000 in 2024 from $46,603,000 in 2023 [507]. - The interest rate for each tranche is 7.5% plus the greater of Adjusted SOFR or 2.0%, with a minimum interest rate of 9.5% [509]. - The Company recorded interest expense of $756,000 for the Revenue Participation Agreement for the years ended December 31, 2024, 2023, and 2022 [510]. Stock-Based Compensation - Total stock-based compensation expense for the year ended December 31, 2024, was $15.906 million, compared to $14.418 million in 2023 [521]. - The Company granted 1,010,671 Restricted Stock Units (RSUs) during the year ended December 31, 2024, with an average fair value of $8.79 per share [527]. - The total unrecognized compensation costs related to unvested PSU awards amounted to approximately $8,826,000, expected to be recognized over a weighted-average period of 1.7 years [535].

Axogen, Inc. (NASDAQ:AXGN) Q4 2024 Earnings Conference Call February 25, 2025 8:00 AM ET Company Participants Michael Dale - Chairman and Chief Executive Officer Nir Naor - Chief Financial Officer Jens Kemp - Chief Marketing Officer Conference Call Participants Chris Pasquale - Nephron Research Michael Sarcone - Jefferies Caitlin Cronin - Canaccord Genuity Mike Kratky - Leerink Partners Jayson Bedford - Raymond James Ross Osborn - Cantor Fitzgerald Dave Turkaly - Citizens JMP Operator Good morning everyone. ...

AxoGen (AXGN) Q4 2024 Earnings Call February 25, 2025 05:21 PM ET Company Participants Michael Dale - President, CEO & Board DirectorJens Schroeder Kemp - Chief Marketing OfficerNir Naor - Chief Financial OfficerChris Pasquale - Partner - Medical Devices & SuppliesCaitlin Cronin - DirectorMike Kratky - Senior Managing Director, Medical Devices and Technology Equity ResearchJayson Bedford - Managing Director, Equity Research Conference Call Participants Michael Sarcone - AnalystRoss Osborn - Director, Lead R ...

Core Insights - Axogen, Inc. will hold its Analyst & Investor Day on March 4, 2025, from 9am to 12pm Eastern, featuring key executives discussing business strategies and financial objectives [1][2]. Company Overview - Axogen is a leader in developing and marketing surgical solutions for peripheral nerve injuries, focusing on restoring nerve function and quality of life for patients [4]. - The company offers a comprehensive portfolio of products for both scheduled non-trauma and emergent trauma procedures, addressing various nerve-related conditions [5]. Product Portfolio - Key products include: - Avance Nerve Graft: A processed human nerve allograft for bridging severed nerves [6]. - Axoguard Nerve Connector: An aid for tensionless repair of severed nerves [6]. - Axoguard Nerve Protector: A product to protect and reinforce damaged nerves [6]. - Axoguard HA+ Nerve Protector: A next-generation technology for nerve injury protection [6]. - Avive+ Soft Tissue Matrix: An amniotic membrane allograft for tissue protection during repair [6]. - Axoguard Nerve Cap: A product to protect nerve ends and reduce neuroma development [6]. - The product portfolio is available in multiple countries, including the United States, Canada, Germany, the United Kingdom, Spain, and South Korea [6]. Event Details - A live webcast of the Analyst & Investor Day will be available on Axogen's investor relations website, with a replay accessible for 90 days post-event [3].

Core Insights - Axogen, Inc. will hold its Analyst & Investor Day on March 4, 2025, from 9am to 12pm Eastern, featuring key executives discussing business strategies and financial objectives [1][2]. Company Overview - Axogen is a leader in developing and marketing surgical solutions for peripheral nerve injuries, focusing on restoring nerve function and quality of life for patients [4]. - The company offers a comprehensive portfolio of products for peripheral nerve repair, addressing both scheduled non-trauma procedures and emergent trauma procedures [5]. Product Portfolio - Key products include: - Avance® Nerve Graft: A processed human nerve allograft for bridging severed nerves [6]. - Axoguard Nerve Connector®: An aid for tensionless repair of severed nerves [6]. - Axoguard Nerve Protector®: A product to protect damaged nerves and reinforce reconstruction [6]. - Axoguard HA+ Nerve Protector™: A next-generation technology for nerve injury protection [6]. - Avive+ Soft Tissue Matrix™: An amniotic membrane allograft for tissue repair [6]. - Axoguard Nerve Cap®: A product to protect nerve ends and reduce painful neuroma development [6]. - The product portfolio is available in multiple countries, including the United States, Canada, Germany, the United Kingdom, Spain, and South Korea [6].

ALACHUA, Fla. and TAMPA, Fla., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today reported financial results and business highlights for the fourth quarter and full-year ended December 31, 2024. Fourth Quarter 2024 Financial Results and Business Highlights Fourth quarter revenue was $49.4 million, a 15.1% increase compared to the fourth quarter of 2023.Gross margin was 76.1% for the fou ...